Trials / Completed
CompletedNCT01441973
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
A Phase 2 Biomarker Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether elotuzumab will improve response in patients with high risk smoldering myeloma who have more CD56\^dim cells (a marker for the health of the body's immune system)
Detailed description
Intervention model: Dosing is sequential
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Elotuzumab (BMS-901608; HuLuc63) |
Timeline
- Start date
- 2011-12-28
- Primary completion
- 2014-05-30
- Completion
- 2017-01-17
- First posted
- 2011-09-28
- Last updated
- 2018-01-23
- Results posted
- 2016-01-29
Locations
12 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01441973. Inclusion in this directory is not an endorsement.